Cirrhosis nursing: pathophysiology, complications, and care

Cirrhosis affects approximately 4.5 million Americans, accounts for over 50,000 deaths annually in the United States, and ranks among the top conditions nursing students will encounter on med-surg, ICU, and hepatology rotations. It is a chronic, progressive, and irreversible remodeling of the liver where repeated injury replaces functional hepatocytes with fibrotic scar tissue. Understanding the pathophysiology, recognizing the difference between compensated and decompensated stages, and knowing which complications require immediate intervention are all tested heavily on the NCLEX and essential in clinical practice.

This reference covers cirrhosis from the nursing perspective: what drives the disease process, how complications develop, priority assessments, interventions organized by complication, medications with nursing considerations, patient education, and NCLEX review tips. For scoring tools (Child-Pugh and MELD), hepatic encephalopathy grading, and hepatorenal syndrome details, see the liver failure nursing reference — this article cross-links rather than duplicating that content.

The transition from compensated to decompensated cirrhosis is a pivotal clinical event. Decompensation is defined by the first occurrence of ascites, variceal hemorrhage, hepatic encephalopathy, or jaundice. Once a patient crosses this threshold, the disease trajectory changes dramatically.

Pathophysiology: from injury to portal hypertension

Cirrhosis develops through a predictable cascade of cellular events, regardless of the underlying cause. Understanding this sequence helps you connect the disease mechanism to the clinical complications you will assess and manage.

Hepatocyte injury and stellate cell activation

Chronic liver injury — whether from alcohol, viral hepatitis, fatty liver disease, or autoimmune conditions — causes repeated hepatocyte death. Damaged hepatocytes release reactive oxygen species (ROS) and inflammatory cytokines (TGF-beta, TNF-alpha, interleukins). These signals activate hepatic stellate cells (HSCs), which are normally quiescent vitamin A-storing cells in the space of Disse.

Once activated, HSCs transform into myofibroblasts and begin depositing collagen (primarily types I and III) in the perisinusoidal space. This is the fibrosis stage. Concurrently, Kupffer cells (hepatic macrophages) amplify the inflammatory response, creating a self-perpetuating cycle of injury, inflammation, and fibrosis.

Fibrosis to regenerative nodules

As collagen accumulates, it disrupts the normal sinusoidal architecture. The liver attempts to regenerate, but new hepatocytes form within fibrous bands, creating regenerative nodules surrounded by scar tissue. These nodules lack normal vascular connections, so they function poorly despite being composed of living hepatocytes.

The structural distortion has two major consequences:

1. Increased intrahepatic resistance. Fibrotic tissue and regenerative nodules compress hepatic sinusoids and central veins, raising portal venous pressure. This is compounded by an imbalance in vasoactive mediators — cirrhotic sinusoidal endothelial cells produce less nitric oxide (a vasodilator) and more endothelin-1 (a vasoconstrictor), further increasing intrahepatic vascular resistance.

2. Loss of functional hepatocyte mass. As fibrosis progresses, fewer hepatocytes remain functional. Synthetic capacity declines: albumin production falls (causing edema and ascites), clotting factor production decreases (causing coagulopathy), and bilirubin conjugation fails (causing jaundice).

The portal hypertension cascade

Portal hypertension (portal venous pressure >5 mmHg, clinically significant at ≥10 mmHg) is the central driver of most cirrhosis complications. Elevated portal pressure forces blood through collateral pathways — portosystemic shunts that bypass the liver entirely. These collaterals form varices (esophageal, gastric, rectal), cause splenomegaly with resultant thrombocytopenia, and create caput medusae (visible periumbilical veins).

Simultaneously, splanchnic vasodilation from excessive nitric oxide production in the mesenteric circulation reduces effective circulating volume. The body compensates by activating the renin-angiotensin-aldosterone system (RAAS) and antidiuretic hormone (ADH), leading to sodium and water retention — the mechanism behind ascites and dilutional hyponatremia.

Causes of cirrhosis

The three most common causes in the United States are:

• Alcohol-related liver disease — typically requires >10 years of heavy drinking (>2 drinks/day for women, >3 for men)
• Non-alcoholic steatohepatitis (NASH) — now termed metabolic dysfunction-associated steatohepatitis (MASH), the fastest-growing cause, linked to obesity and metabolic syndrome
• Chronic hepatitis C — declining since the introduction of direct-acting antivirals but still prevalent

Other causes include chronic hepatitis B, autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), hemochromatosis, Wilson disease, and alpha-1 antitrypsin deficiency. In clinical practice, determining the etiology is essential because some causes are treatable (viral hepatitis, autoimmune hepatitis, Wilson disease), which can halt or slow progression.

Complications and nursing implications

Each major complication of cirrhosis has specific nursing assessment and intervention priorities. The complications below are organized from most common to most acutely life-threatening.

Ascites

Ascites is the most common complication of decompensated cirrhosis, occurring in approximately 60% of patients with compensated cirrhosis within 10 years of diagnosis. Fluid accumulates in the peritoneal cavity due to three converging mechanisms: portal hypertension pushing fluid out of the splanchnic vasculature, hypoalbuminemia reducing plasma oncotic pressure, and RAAS-driven sodium and water retention.

Nursing assessment: Measure abdominal girth daily at the same anatomical landmark (typically the umbilicus), with the patient supine. Track daily weights at the same time, on the same scale, wearing similar clothing. Strict intake and output documentation is essential. Assess for shifting dullness and fluid wave on physical exam. Monitor serum albumin, sodium, and renal function.

Management and nursing interventions:

• Sodium restriction: 2 g/day (2,000 mg). Educate the patient that most dietary sodium comes from processed foods, restaurant meals, and condiments — counting only “added salt” dramatically underestimates intake.
• Diuretics: The standard combination is spironolactone 100 mg plus furosemide 40 mg daily (the 100:40 ratio). This ratio maintains potassium balance because spironolactone is potassium-sparing while furosemide wastes potassium. Doses can be titrated upward together while maintaining this ratio (200:80, 400:160 maximum). Monitor potassium, sodium, creatinine, and daily weights. Target weight loss is 0.5 kg/day without peripheral edema, or 1.0 kg/day with peripheral edema.
• Therapeutic paracentesis: Large-volume paracentesis (LVP) is performed for tense or refractory ascites. When >5 L of fluid is removed, administer albumin 6–8 g per liter removed to prevent post-paracentesis circulatory dysfunction. Nursing care includes monitoring vital signs during and after the procedure, measuring the total volume drained, assessing the puncture site for leakage, and sending fluid for cell count, culture, and albumin (to calculate the serum-ascites albumin gradient, or SAAG).

Spontaneous bacterial peritonitis

Spontaneous bacterial peritonitis (SBP) is a bacterial infection of ascitic fluid without an identifiable surgical source. It occurs in 10–30% of hospitalized cirrhosis patients with ascites and carries a mortality rate of approximately 20%.

Diagnosis: Diagnostic paracentesis is performed whenever a patient with ascites develops fever, abdominal pain or tenderness, new or worsening encephalopathy, renal function decline, or unexplained clinical deterioration. The diagnostic threshold is an ascitic fluid polymorphonuclear neutrophil (PMN) count >250 cells/mm³. Treatment begins immediately on clinical suspicion — do not wait for culture results.

Common organisms: Escherichia coli, Klebsiella pneumoniae, and streptococcal species (gram-negative organisms predominate).

Treatment: IV cefotaxime (2 g every 8 hours for 5 days) is first-line empiric therapy. IV albumin (1.5 g/kg on day 1 and 1.0 g/kg on day 3) is administered concurrently — this albumin protocol has been shown to reduce renal failure and mortality in SBP.

Prophylaxis: After a first episode of SBP, patients receive long-term antibiotic prophylaxis (norfloxacin 400 mg daily or trimethoprim-sulfamethoxazole). Primary prophylaxis is also indicated for patients with ascitic fluid protein <1.5 g/dL combined with either impaired renal function (creatinine ≥1.2 mg/dL) or liver failure (Child-Pugh ≥9 with bilirubin ≥3 mg/dL).

Nursing priority: Suspect SBP early. Any change in mental status, unexplained fever, or abdominal tenderness in a patient with ascites warrants a call to the provider for diagnostic paracentesis. Delayed diagnosis increases mortality significantly.

Portal hypertension and esophageal varices

Portal hypertension drives the formation of esophageal and gastric varices — dilated, thin-walled veins that develop as collateral pathways for portal blood flow. Varices are present in approximately 50% of patients with cirrhosis at diagnosis and carry a first-bleed mortality rate of 15–20%.

Surveillance: All patients with cirrhosis undergo screening esophagogastroduodenoscopy (EGD) at diagnosis. Patients with small varices are rescreened in 1–2 years; those without varices are rescreened in 2–3 years.

Primary prophylaxis: Non-selective beta-blockers (propranolol or nadolol) reduce portal pressure and decrease the risk of a first variceal bleed by approximately 50%. Carvedilol is emerging as a preferred alternative because it provides both beta-blockade and mild alpha-blockade (additional portal pressure reduction). Endoscopic band ligation (EBL) is an alternative for patients who cannot tolerate beta-blockers.

Acute variceal bleeding: This is a medical emergency. For detailed nursing management of variceal hemorrhage — including Blakemore tube care, octreotide infusion, and emergent EBL — see the GI bleed nursing reference. Key nursing actions include establishing two large-bore IV lines, initiating volume resuscitation (transfuse conservatively — target hemoglobin 7–8 g/dL in cirrhosis to avoid raising portal pressure), administering IV octreotide, and anticipating emergent endoscopy.

TIPS (transjugular intrahepatic portosystemic shunt): TIPS is a radiologic procedure that creates a shunt between the portal and hepatic veins, reducing portal pressure. Indications include refractory variceal bleeding unresponsive to endoscopic therapy, refractory ascites, and Budd-Chiari syndrome. Post-TIPS nursing considerations include monitoring for hepatic encephalopathy (the shunt diverts portal blood past the liver, increasing ammonia delivery to the brain), assessing for shunt thrombosis (worsening ascites or recurrent bleeding), and monitoring liver function labs (TIPS can worsen hepatic function in patients with advanced disease).

Hepatic encephalopathy

Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome caused by neurotoxins — primarily ammonia — that accumulate when the liver cannot clear them. Portosystemic shunting (whether natural collaterals or a TIPS procedure) compounds the problem by delivering ammonia-rich portal blood directly to systemic circulation.

For the complete West Haven grading system, precipitating factors, and nursing assessment details, see the hepatic encephalopathy section of the liver failure reference. Below are the cirrhosis-specific management priorities.

Precipitating factors to assess: GI bleeding (blood is a protein load that increases ammonia production), infection (including SBP), constipation, dehydration, electrolyte imbalances (particularly hypokalemia and metabolic alkalosis, which increase ammonia crossing the blood-brain barrier), sedative use (benzodiazepines, opioids), and excessive dietary protein.

Key assessment finding — asterixis: Asterixis (flapping tremor) is the hallmark sign of Grade 2 HE. To test, ask the patient to extend both arms with wrists dorsiflexed and fingers spread — an involuntary, irregular flapping indicates asterixis. This is a high-yield NCLEX item.

Management:

• Lactulose is first-line therapy. It works by two mechanisms: osmotic laxative effect (traps ammonia in the gut lumen as ammonium) and acidification of colonic pH (converts ammonia [NH3] to non-absorbable ammonium [NH4+]). Titration goal: 2–4 soft stools per day. Too few stools means insufficient ammonia clearance; too many means risk of dehydration and electrolyte depletion, which can paradoxically worsen encephalopathy. This titration target is an NCLEX favorite.
• Rifaximin (550 mg twice daily) is added as adjunctive therapy to reduce ammonia-producing gut bacteria. It is a non-absorbable antibiotic that acts locally in the GI tract with minimal systemic absorption. Rifaximin is especially important for preventing HE recurrence after a first episode.
• Dietary protein: Current guidelines recommend maintaining normal protein intake (1.2–1.5 g/kg/day) in most patients with HE. Protein restriction was formerly standard practice but is now discouraged because cirrhotic patients are already catabolic and protein-malnourished — restricting protein accelerates sarcopenia without meaningful ammonia reduction.
• Zinc supplementation (220 mg zinc sulfate daily) may be beneficial because zinc is a cofactor in the urea cycle. Zinc deficiency is common in cirrhosis and may impair ammonia detoxification.

Hepatorenal syndrome

Hepatorenal syndrome (HRS) is renal failure occurring in the context of advanced liver disease, without intrinsic kidney pathology. The kidneys themselves are structurally normal — the problem is extreme renal vasoconstriction driven by splanchnic vasodilation and reduced effective circulating volume. For detailed pathophysiology and Type 1 versus Type 2 classification, see the liver failure reference.

Nursing essentials: Monitor urine output hourly — oliguria (<400 mL/day) with low urine sodium (<10 mEq/L) in a cirrhosis patient should raise immediate suspicion for HRS. Trend serum creatinine. Avoid nephrotoxic medications (NSAIDs, aminoglycosides, IV contrast when possible). Type 1 HRS (rapid creatinine rise, median survival ~2 weeks without treatment) is an emergency requiring ICU transfer and vasopressor support (terlipressin or midodrine plus octreotide with albumin infusion).

Coagulopathy

The liver synthesizes nearly all clotting factors (I, II, V, VII, IX, X, XI, XII, XIII) plus anticoagulant proteins (protein C, protein S, antithrombin). Cirrhosis creates a complex coagulation state — patients are at increased risk of both bleeding (reduced factor synthesis, thrombocytopenia from hypersplenism) and thrombosis (reduced protein C and S).

Nursing actions: Monitor INR, PT, PTT, fibrinogen, and platelet count trending. Implement bleeding precautions: soft toothbrush, electric razor, avoid rectal temperatures, hold pressure on venipuncture sites for at least 5 minutes, and minimize unnecessary needle sticks. Assess for bleeding signs — melena, hematemesis, hematuria, petechiae, ecchymoses, gingival bleeding. Vitamin K may be administered but only helps if the liver retains enough functional capacity to synthesize clotting factors. For active bleeding, fresh frozen plasma (FFP) or cryoprecipitate may be ordered. Review the lab values cheat sheet for coagulation panel normal ranges.

Malnutrition and sarcopenia

Malnutrition affects 50–90% of patients with decompensated cirrhosis and is an independent predictor of mortality. Mechanisms include poor oral intake (early satiety from ascites, dysgeusia, nausea), impaired nutrient absorption, increased resting energy expenditure, and impaired hepatic glycogen storage causing accelerated starvation physiology — cirrhotic patients begin gluconeogenesis from amino acids after just an overnight fast (compared to ~72 hours in healthy individuals).

Nursing interventions: Encourage small, frequent meals (4–6 per day) to avoid prolonged fasting. A late-evening snack (before bed) is specifically recommended to reduce overnight catabolism and has been shown to improve nitrogen balance. Caloric targets are 25–35 kcal/kg/day. Protein intake should be maintained at 1.2–1.5 g/kg/day. Consult a dietitian early. Monitor prealbumin for shorter-term nutritional trends (half-life ~2 days) rather than albumin (half-life ~21 days).

Nursing assessment priorities

A focused assessment for the cirrhosis patient integrates findings from every organ system affected by portal hypertension and hepatocellular failure. Use the head-to-toe assessment framework and look specifically for the following:

Neurological: Assess orientation and cognition at every shift. Test for asterixis. Monitor for sleep-wake cycle reversal, personality changes, slowed responses — these may be the earliest signs of encephalopathy that family members notice before nursing staff. Use the Glasgow Coma Scale for grade 3–4 encephalopathy.

Integumentary: Inspect for jaundice (scleral icterus appears before skin changes), spider angiomas (most common on face, neck, upper chest, and arms), palmar erythema, caput medusae (dilated periumbilical veins), bruising, petechiae, excoriation from pruritus, and peripheral edema (sacral in bedridden patients, pedal in ambulatory patients).

Abdominal: Assess abdominal girth (document landmark used), auscultate bowel sounds (hypoactive in severe ascites), palpate for hepatomegaly (early cirrhosis) or a small, shrunken liver (late cirrhosis), assess for shifting dullness and fluid wave, and inspect for caput medusae and umbilical hernia (common with tense ascites).

Cardiovascular: Hyperdynamic circulation is common in advanced cirrhosis — tachycardia with bounding pulse and low blood pressure from splanchnic vasodilation. Orthostatic hypotension may indicate volume depletion or over-diuresis.

Renal: Strict intake and output. Monitor urine color and output hourly if HRS is a concern. Track daily weights. Monitor BUN, creatinine, and serum sodium (dilutional hyponatremia is common and a poor prognostic sign).

Musculoskeletal: Assess muscle mass, grip strength, and functional status. Sarcopenia (muscle wasting) is prevalent and affects prognosis. Temporal muscle wasting is an early visible indicator.

Nursing interventions by complication

Medications table

Patient education

Patient education in cirrhosis must be practical, specific, and repeated at every encounter because hepatic encephalopathy can impair the patient’s ability to retain information. Include family members and caregivers in all teaching sessions.

Dietary guidance: Adhere to a 2 g/day sodium restriction. Read food labels — aim for <600 mg sodium per meal. Maintain adequate protein intake (1.2–1.5 g/kg/day) despite previous teaching that may have emphasized protein restriction. Eat small, frequent meals and include a bedtime snack to prevent overnight muscle breakdown. Avoid raw shellfish (Vibrio vulnificus risk in cirrhosis carries a 50% mortality rate).

Alcohol avoidance: Complete and permanent abstinence is essential regardless of cirrhosis etiology. Even moderate alcohol consumption accelerates fibrosis in all forms of liver disease. Refer to substance use counseling and community support resources.

Medication adherence: Take lactulose as prescribed and report to the provider if stool frequency drops below 2 or exceeds 4 per day. Take diuretics in the morning to avoid nocturia. Avoid all NSAIDs (ibuprofen, naproxen, aspirin) — these impair renal perfusion and increase GI bleeding risk. Acetaminophen is permitted but limited to <2 g/day in cirrhosis. Avoid herbal supplements unless approved by the hepatologist — many are hepatotoxic.

When to seek emergency care: Vomiting blood or passing black tarry stools, sudden abdominal swelling with fever or pain, confusion or difficulty concentrating (family should be educated on recognizing early encephalopathy), decreased urine output, or falls.

Surveillance: Patients need regular follow-up including variceal screening (EGD every 1–3 years depending on findings), hepatocellular carcinoma screening (abdominal ultrasound and alpha-fetoprotein every 6 months), and lab monitoring (liver function tests, CBC, renal panel, ammonia as indicated).

NCLEX tips

1. Compensated vs. decompensated: Know the difference. Compensated cirrhosis may be asymptomatic — decompensation begins with the first episode of ascites, variceal bleeding, encephalopathy, or jaundice. This distinction drives nursing priorities.

2. Asterixis = encephalopathy sign: Test for asterixis by having the patient dorsiflex the wrists with arms extended and fingers spread. A flapping tremor indicates Grade 2 or higher hepatic encephalopathy. High-yield NCLEX finding.

3. Lactulose titration target: 2–4 soft stools per day. If the patient has fewer than 2, the dose is too low. More than 4 risks dehydration and electrolyte imbalances that can worsen encephalopathy. Know this number.

4. Spironolactone:furosemide ratio is 100:40. This maintains potassium balance. If a question asks about diuretic therapy in cirrhotic ascites, look for this pairing and ratio.

5. SBP diagnostic threshold: PMN >250 cells/mm³ in ascitic fluid. Treatment starts immediately on suspicion — antibiotics and albumin. A patient with ascites who develops fever and confusion needs diagnostic paracentesis urgently.

6. Hepatorenal syndrome = functional renal failure. The kidneys are structurally normal. Low urine sodium (<10 mEq/L) and oliguria in a cirrhosis patient should trigger concern. Type 1 is rapidly progressive and life-threatening.

7. Avoid NSAIDs in cirrhosis. NSAIDs impair renal prostaglandin-mediated perfusion and increase GI bleeding risk. For pain, acetaminophen <2 g/day is preferred. This comes up frequently in NCLEX medication questions.

8. Post-paracentesis albumin: When >5 L is removed during large-volume paracentesis, administer albumin 6–8 g per liter removed. Without albumin replacement, post-paracentesis circulatory dysfunction can cause renal failure.

9. Protein restriction is outdated. Current evidence supports maintaining protein intake at 1.2–1.5 g/kg/day in hepatic encephalopathy. Restricting protein worsens sarcopenia and outcomes. If a question offers protein restriction as a nursing intervention, it is likely the distractor.

10. TIPS increases encephalopathy risk. A TIPS procedure shunts portal blood past the liver, increasing ammonia delivery to the brain. Any patient post-TIPS needs increased neurological monitoring and likely prophylactic lactulose/rifaximin.

Related pages

• Liver failure nursing: assessment, interventions, and complications — Child-Pugh scoring, MELD score, hepatic encephalopathy grading, hepatorenal syndrome details
• GI bleed nursing: assessment, interventions, and clinical management — variceal hemorrhage management, Blakemore tube, octreotide
• Pancreatitis nursing — alcohol-related pancreatitis frequently co-occurs with cirrhosis
• Nursing lab values cheat sheet — liver function tests, coagulation panel, CBC normal ranges
• Electrolyte imbalances nursing reference — hyponatremia, hypokalemia, and hyperkalemia management in cirrhosis
• ABG interpretation — respiratory alkalosis (common in cirrhosis from hyperventilation) and metabolic alkalosis
• Head-to-toe assessment — systematic physical assessment framework
• ADPIE nursing process — structured care planning for complex patients
• SBAR communication — critical for escalating encephalopathy or variceal bleeding
• Glasgow Coma Scale — neurological assessment for grade 3–4 encephalopathy
• Drug classifications nursing — diuretics, beta-blockers, antibiotics
• Sepsis nursing — SBP can progress to sepsis in cirrhosis patients